IRIS
VOSO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 73.108
AS - Asia 8.491
EU - Europa 6.215
SA - Sud America 1.493
AF - Africa 143
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 26
Totale 89.507
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 72.905
SG - Singapore 3.963
CN - Cina 1.512
IT - Italia 1.384
BR - Brasile 1.243
RU - Federazione Russa 1.090
HK - Hong Kong 986
IE - Irlanda 771
VN - Vietnam 685
UA - Ucraina 682
DE - Germania 637
KR - Corea 500
FR - Francia 430
GB - Regno Unito 363
FI - Finlandia 290
JP - Giappone 248
IN - India 142
NL - Olanda 126
CA - Canada 103
PL - Polonia 98
SE - Svezia 96
AR - Argentina 88
BD - Bangladesh 75
AT - Austria 73
ID - Indonesia 69
MX - Messico 59
ES - Italia 53
ZA - Sudafrica 48
CO - Colombia 39
IQ - Iraq 38
TR - Turchia 32
AU - Australia 30
EC - Ecuador 30
PK - Pakistan 24
VE - Venezuela 24
PY - Paraguay 23
UZ - Uzbekistan 23
BE - Belgio 22
IR - Iran 22
PH - Filippine 22
EG - Egitto 21
MA - Marocco 21
EU - Europa 19
KZ - Kazakistan 17
CL - Cile 16
LT - Lituania 16
SA - Arabia Saudita 15
JO - Giordania 14
KE - Kenya 13
TH - Thailandia 13
PE - Perù 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
DZ - Algeria 11
AZ - Azerbaigian 9
CZ - Repubblica Ceca 9
TN - Tunisia 9
DO - Repubblica Dominicana 8
NP - Nepal 8
RO - Romania 8
AL - Albania 7
IL - Israele 7
MY - Malesia 7
TW - Taiwan 7
CR - Costa Rica 6
HR - Croazia 6
JM - Giamaica 6
KG - Kirghizistan 6
BG - Bulgaria 5
BO - Bolivia 5
PS - Palestinian Territory 5
SN - Senegal 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BN - Brunei Darussalam 4
GE - Georgia 4
GR - Grecia 4
GT - Guatemala 4
HU - Ungheria 4
MK - Macedonia 4
RS - Serbia 4
TT - Trinidad e Tobago 4
LU - Lussemburgo 3
MD - Moldavia 3
NG - Nigeria 3
OM - Oman 3
PT - Portogallo 3
QA - Qatar 3
SY - Repubblica araba siriana 3
A1 - Anonimo 2
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
BZ - Belize 2
CY - Cipro 2
HN - Honduras 2
KW - Kuwait 2
Totale 89.472
Salva come PNG Salva come JPEG
Città #
Houston 22.122
Woodbridge 18.291
Wilmington 16.090
Fairfield 2.305
Singapore 2.180
Ann Arbor 1.484
Ashburn 1.428
San Jose 999
Hong Kong 974
Seattle 907
Cambridge 834
Chandler 819
Dublin 710
Jacksonville 592
Dearborn 574
Beijing 566
Medford 526
Rome 456
The Dalles 344
Santa Clara 338
Dallas 319
New York 309
Lawrence 252
Ho Chi Minh City 235
Lauterbourg 228
Tokyo 221
Los Angeles 219
Council Bluffs 213
Moscow 176
Hanoi 141
Hangzhou 131
Buffalo 127
San Diego 118
Milan 115
São Paulo 110
Menlo Park 102
Helsinki 91
London 91
Nuremberg 70
North Bergen 67
Orem 67
Chicago 64
Redondo Beach 59
Boardman 57
Creede 52
Munich 52
Center 51
Jakarta 43
Seoul 43
Warsaw 42
Norwalk 41
Engelhard 40
Frankfurt am Main 39
Kraków 39
Shanghai 38
Atlanta 37
Brooklyn 35
Toronto 35
Da Nang 34
Denver 34
Rio de Janeiro 34
Chennai 33
Zhengzhou 33
Guangzhou 32
Nanjing 32
Vienna 32
Hefei 31
Montreal 31
Mountain View 28
Phoenix 28
Stockholm 27
Bologna 26
Hackensack 26
Verona 26
Belo Horizonte 25
Haiphong 25
Baghdad 24
Florence 24
Redwood City 24
San Francisco 24
Amsterdam 23
Brasília 23
Lappeenranta 23
Johannesburg 22
Naples 22
Curitiba 20
Guarulhos 19
Brussels 18
Detroit 18
Kunming 18
Pune 18
Dhaka 17
Porto Alegre 17
Mexico City 16
Mumbai 16
Tashkent 16
Boston 15
City of London 15
Madrid 15
Manchester 15
Totale 77.707
Salva come PNG Salva come JPEG
Nome #
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation 2.378
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias 1.668
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS 1.631
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15 1.259
Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis 1.186
Therapy-related leukemia and myelodysplasia: susceptibility and incidence 506
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 506
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 501
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 500
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 473
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 464
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 461
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 461
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 460
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 459
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia 459
Clonal evolution in therapy-related neoplasms 457
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 456
Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor 453
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 448
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy 448
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 447
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 445
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 441
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 441
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression 440
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin 440
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 438
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia 438
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 437
Panobinostat for the treatment of acute myelogenous leukemia 436
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer 434
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery 431
New treatments for myelodysplastic syndromes 430
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 429
Therapy related leukemias: susceptibility, prevention and treatment 428
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 427
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 427
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 426
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms 425
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 423
Small lymphocytic lymphoma in a patient with Fabry disease 422
Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease 422
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 421
Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms 420
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System 420
Prevalence of obesity in young adults with acute lymphoblastic leukemia 419
Why methylation is not a marker predictive of response to hypomethylating agents 419
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 419
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 417
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 416
Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation 415
In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study 414
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 414
Hepato-splenic mycotic abscesses in patients with acute leukemia 414
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? 412
Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects 412
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 411
Mobilization and selection of CD34+ cells 411
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 409
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 407
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes 406
Epigenetic changes in therapy-related MDS/AML 406
Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia 404
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 404
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia 404
Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients 403
Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre 403
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma 402
Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer 402
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 402
High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment 401
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 401
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia 401
Incidence and susceptibility to therapy-related myeloid neoplasms 400
Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia 400
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 400
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression 399
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 398
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 398
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 397
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha 397
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 397
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma 396
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 396
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 396
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 396
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 394
Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B 393
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content 393
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 392
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 391
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 391
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 391
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias 390
Treatment of low-blast count AML using hypomethylating agents 390
The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia 390
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 389
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 388
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 386
Totale 48.118
Salva come PNG Salva come JPEG
Categoria #
all - tutte 215.364
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 215.364
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021820 0 0 0 0 0 0 0 0 0 266 447 107
2021/20222.487 118 293 127 61 78 198 129 148 178 143 268 746
2022/20232.760 339 173 135 270 180 696 484 119 205 20 77 62
2023/20241.297 126 37 149 56 124 346 67 33 51 40 30 238
2024/20256.762 179 1.438 783 446 133 355 681 337 799 568 568 475
2025/202610.355 916 611 1.522 879 966 366 1.439 1.353 1.357 946 0 0
Totale 90.902